Employees: 11 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2008-04-01 (18 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PARENTIS-EN-BORN (40160), Landes
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE DUSSARRAT : revenue, balance sheet and financial ratios
PHARMACIE DUSSARRAT is a French company
founded 18 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PARENTIS-EN-BORN (40160),
this company of category PME
shows in 2018 a revenue of 2.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DUSSARRAT (SIREN 505069948)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
2 216 812 €
N/C
Net income
348 339 €
314 378 €
256 129 €
243 675 €
209 886 €
202 730 €
216 902 €
188 753 €
189 313 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
270 148 €
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
8.5%
N/C
Revenue and income statement
In 2025, PHARMACIE DUSSARRAT generates positive net income of 348 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 189 k€ -> 348 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
348 339 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 1%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 82%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
1.376%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
82.426%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
13.233
11.135
7.177
3.507
1.194
2.787
2.08
1.663
1.376
Financial autonomy
79.086
80.465
84.116
86.234
88.373
84.692
83.79
83.462
82.426
Repayment capacity
None
1.249
None
None
None
None
None
None
None
Cash flow / Revenue
None%
8.779%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
1.382025
2023
2024
2025
Q1: 13.71
Med: 49.76
Q3: 129.07
Excellent
In 2025, the debt ratio of PHARMACIE DUSSARRAT (1.38) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
82.43%2025
2023
2024
2025
Q1: 33.42%
Med: 53.71%
Q3: 72.08%
Excellent+8 pts over 3 years
In 2025, the financial autonomy of PHARMACIE DUSSARRAT (82.4%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 221.32. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
190.413
197.819
219.257
205.371
190.263
189.705
198.047
213.111
221.317
Interest coverage
None
1.522
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
221.322025
2023
2024
2025
Q1: 131.03
Med: 182.29
Q3: 258.7
Good+10 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE DUSSARRAT (221.32) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 109 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 1123 days. Excellent situation: suppliers finance 1014 days of the operating cycle (retail model).
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
109 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
1123 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DUSSARRAT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
320 152 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
Inventory turnover (days)
0
38
0
0
0
0
0
0
0
Customer payment term (days)
0
5
0
0
0
165
309
152
109
Supplier payment term (days)
0
53
0
0
0
1016
1104
1017
1123
Positioning of PHARMACIE DUSSARRAT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE DUSSARRAT is estimated at
5 533 406 €
(range 3 754 995€ - 8 682 676€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
3754k€5533k€8682k€
5 533 406 €Range: 3 754 995€ - 8 682 676€
NAF 5 année 2025
Valuation method used
Net Income Multiple
348 339 €
×
15.9x
=5 533 406 €
Range: 3 754 996€ - 8 682 677€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DUSSARRAT with other companies in the same sector:
Frequently asked questions about PHARMACIE DUSSARRAT
What is the revenue of PHARMACIE DUSSARRAT ?
The revenue of PHARMACIE DUSSARRAT in 2018 is 2.2 M€.
Is PHARMACIE DUSSARRAT profitable?
Yes, PHARMACIE DUSSARRAT generated a net profit of 348 k€ in 2025.
Where is the headquarters of PHARMACIE DUSSARRAT ?
The headquarters of PHARMACIE DUSSARRAT is located in PARENTIS-EN-BORN (40160), in the department Landes.
Where to find the tax return of PHARMACIE DUSSARRAT ?
The tax return of PHARMACIE DUSSARRAT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DUSSARRAT operate?
PHARMACIE DUSSARRAT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart